Legal & General Group Plc reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,800 shares of the company’s stock after selling 5,011 shares during the quarter. Legal & General Group Plc’s holdings in Neurocrine Biosciences were worth $3,910,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Neurocrine Biosciences by 2.8% during the 1st quarter. BlackRock Inc. now owns 4,908,495 shares of the company’s stock valued at $407,061,000 after purchasing an additional 132,749 shares during the period. First Trust Advisors LP grew its stake in shares of Neurocrine Biosciences by 5.6% during the 2nd quarter. First Trust Advisors LP now owns 979,671 shares of the company’s stock valued at $96,243,000 after acquiring an additional 52,200 shares during the period. OppenheimerFunds Inc. grew its stake in shares of Neurocrine Biosciences by 3.7% during the 1st quarter. OppenheimerFunds Inc. now owns 834,998 shares of the company’s stock valued at $69,246,000 after acquiring an additional 29,751 shares during the period. Rock Springs Capital Management LP grew its stake in shares of Neurocrine Biosciences by 24.7% during the 1st quarter. Rock Springs Capital Management LP now owns 606,200 shares of the company’s stock valued at $50,272,000 after acquiring an additional 120,200 shares during the period. Finally, American Century Companies Inc. grew its stake in shares of Neurocrine Biosciences by 14.0% during the 2nd quarter. American Century Companies Inc. now owns 566,895 shares of the company’s stock valued at $55,692,000 after acquiring an additional 69,701 shares during the period.

NASDAQ NBIX opened at $121.05 on Tuesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19. Neurocrine Biosciences, Inc. has a 12 month low of $56.83 and a 12 month high of $126.98. The company has a market capitalization of $10.82 billion, a P/E ratio of -74.68, a price-to-earnings-growth ratio of 37.08 and a beta of 0.41.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The company had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $84.11 million. During the same period in the previous year, the firm earned ($0.68) EPS. The firm’s revenue was up 1428.4% compared to the same quarter last year. equities analysts forecast that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current year.

In related news, insider Dimitri E. Grigoriadis sold 23,022 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $110.00, for a total value of $2,532,420.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by insiders.

A number of research analysts recently issued reports on NBIX shares. BidaskClub downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Barclays set a $100.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Friday, June 8th. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences to $127.00 and gave the company an “overweight” rating in a research note on Monday, July 16th. Robert W. Baird reiterated an “outperform” rating and set a $122.00 price objective (up from $100.00) on shares of Neurocrine Biosciences in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group boosted their price objective on Neurocrine Biosciences to $124.00 and gave the company a “buy” rating in a research note on Monday, July 30th. One analyst has rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $122.11.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C.

See Also: Return on Equity (ROE)

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.